Availability and rationality of fixed dose combinations available in Kaduna, Nigeria

Keywords: Drug Combinations, Drug Therapy, Combination, Medication Adherence, Developing Countries, Nigeria

Abstract

Background: Fixed-dose drug combinations (FDCs), are combinations of two or more active drugs in a single dosage form. Despite the advantages obtained from the use of these agents, there is increasing evidence questioning the rationality of several FDCs found in pharmaceutical markets-especially those in developing countries like Nigeria.

Objectives: To describe the availability of FDCs in drug retailing outlets located in Kaduna Nigeria, and to assess FDC registration status and inclusion on national and international essential medicines lists (EMLs). Rationality of selected FDCs was also assessed.

Methods: A cross-sectional survey was carried out from June to September 2018 in 60 registered pharmacies and patent medicine shops selected through multi-stage sampling. A data collection form was used to obtain information on the generic names and strengths of the active ingredients of the FDCs, their country of manufacture and evidence of registration with the Nigerian drug regulatory agency. To assess rationality, a scoring rubric developed from earlier studies was used. Data collected was coded and entered into a Microsoft excel 2016 spreadsheet for analysis. Descriptive statistics (frequencies and percentages) were used to report the data collected.

Results: FDCs encountered included 74 oral tablets/capsules, 52 oral liquids and 23 topical semi solids. Majority of the available FDCs were registered by Nigerian drug regulatory agency (91.5%), although only 8.5% and 6.5% in total were included on the Nigerian EML and the WHO model list respectively. Of the 99 FDCs assessed for rationality, 58 (58.6%) were found to be rational. Irrational FDCs included drugs acting on the respiratory tract (29.3%), analgesics (26.8%) and anti-infectives (22%).

Conclusions: A wide variety of FDCs were available in the study area, even though not all of them were rational. There is an urgent need for policy makers within the country to develop better detailed guidelines for FDC registration.

Downloads

Download data is not yet available.

References

Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65(5):795-796. https://doi.org/10.1111/j.1365-2125.2007.03089.x

Wirtz VJ, Mol PG, Verdijk J, Vander Stichele RH, Taxis K. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. Trop Med Int Health. 2013;18(4):416-425. https://doi.org/10.1111/tmi.12068

Poudel A, Mohamed Ibrahim MI, Mishra P, Palaian S. Evaluation of the registration status of fixed-dose drug combinations in Nepal. J Pharm Health Serv Res. 2018;9(1):41-46. https://doi.org/10.1111/jphs.12205

Dalal K, Ganguly B, Gor A. Assessment of rationality of fixed dose combinations approved in CDSCO List. J Clin Diagn Res. 2016;10(4):FC05-FC08. https://doi.org/10.7860/JCDR/2016/17856.7691

Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203-212. https://doi.org/10.3111/13696998.2015.1109518

Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9(11):1453-1462. https://doi.org/10.1080/17512433.2016.1221758

Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018;15(6):e1002584. https://doi.org/10.1371/journal.pmed.1002584

ReAct, Why are fixed dose combinations of antibiotics generally not a good idea?. https://www.reactgroup.org/news-and-views/news-and-opinions/year-2018/why-are-fixed-dose-combinations-of-antibiotics-generally-not-a-good-idea/ (accessed Dec 28, 2018).

Ahmad A, Khan MU, Balkrishnan R. Fixed-dose combination antibiotics in India: global perspectives, Lancet Glob Health. 2016;4(8):e521. https://doi.org/10.1016/S2214-109X(16)30093-6

Poudel A, Mohamed Ibrahim MI, Mishra P, Palaian S. Assessment of the availability and rationality of unregistered fixed dose drug combinations in Nepal: a multicenter cross-sectional study. Glob Health Res Policy. 2017;2:14. https://doi.org/10.1186/s41256-017-0033-z

Shah S, Patel J, Desai M, Dikshit RK. Critical analysis of antimicrobial and respiratory fixed dose combinations available in Indian market. Int J Med Public Health. 2015;5(2):161-164. http://dx.doi.org/10.4103/2230-8598.153828

Roy V, Malhotra R, Tayal V, Bansal A, Gupta KS. Fixed-dose combinations for cough and common cold in India: an assessment of availability and rationality. Fundam Clin Pharmacol. 2011;25(2):258-266. https://doi.org/10.1111/j.1472-8206.2010.00840.x

McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Med. 2015;12(5):e1001826. https://doi.org/10.1371/journal.pmed.1001826

McGettigan P, Roderick P, Kadam A, Pollock A. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019;85(1):59-70. https://doi.org/10.1111/bcp.13503

FMOH, Essential Medicines List Nigeria 6th Edition, Federal Ministry of Health Nigeria, Abuja, 2016.

WHO, WHO Model List of Essential Medicines-20th List, World Health Organization, 2017.

NPC, Population Distribution by Sex, State, LGA & Senatorial District, National Population Commission, Nigeria, Abuja, 2010.

KDSG, Demographics – Kaduna State Government, 2018. https://kdsg.gov.ng/demographics/ (accessed Dec 28, 2018).

PCN, List of Licensed Pharmacists and Licensed Pharmaceutical Premises, Pharmacists Council of Nigeria, Abuja, 2016.

Beyeler N, Liu J, Sieverding M. Systematic review of the role proprietary and patent medicine vendors in healthcare Provision in Nigeria. PLoS One. 2015;10(1):e0117165. https://doi.org/10.1371/journal.pone.0117165

Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265-1276. https://doi.org/10.3109/10837450.2012.660699

Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004;329(7475):1169-1172. https://doi.org/10.1136/bmj.329.7475.1169

Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension. 2010 Feb;55(2):399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816

Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-48.

Kumar S, Goyal A, Gupta YK. Abuse of topical corticosteroids in India: Concerns and the way forward. J Pharmacol Pharmacother. 2016;7(1):1-5. https://doi.org/10.4103/0976-500X.179364

Pande S. Steroid containing fixed drug combinations banned by government of India: A big step towards dermatologic drug safety. Indian J Drugs Dermatol. 2016;2(1):1-2. https://doi.org/10.4103/2455-3972.184102

Published
2019-06-10
How to Cite
1.
Auwal F, Dahiru MN, Abdu-Aguye SN. Availability and rationality of fixed dose combinations available in Kaduna, Nigeria. Pharm Pract (Granada) [Internet]. 2019Jun.10 [cited 2019Sep.17];17(2):1470. Available from: https://pharmacypractice.org/journal/index.php/pp/article/view/1470
Section
Original Research